Dataset Information


92R Monoclonal Antibody Inhibits Human CCR9+ Leukemia Cells Growth in NSG Mice Xenografts.

ABSTRACT: CCR9 is as an interesting target for the treatment of human CCR9+-T cell acute lymphoblastic leukemia, since its expression is limited to immature cells in the thymus, infiltrating leukocytes in the small intestine and a small fraction of mature circulating T lymphocytes. 92R, a new mouse mAb (IgG2a isotype), was raised using the A-isoform of hCCR9 as immunogen. Its initial characterization demonstrates that binds with high affinity to the CCR9 N-terminal domain, competing with the previously described 91R mAb for receptor binding. 92R inhibits human CCR9+ tumor growth in T and B-cell deficient Rag2-/- mice. In vitro assays suggested complement-dependent cytotoxicity and antibody-dependent cell-mediated cytotoxicity as possible in vivo mechanisms of action. Unexpectedly, 92R strongly inhibited tumor growth also in a model with compromised NK and complement activities, suggesting that other mechanisms, including phagocytosis or apoptosis, might also be playing a role on 92R-mediated tumor elimination. Taken together, these data contribute to strengthen the hypothesis of the immune system's opportunistic nature.

SUBMITTER: Somovilla-Crespo B 

PROVIDER: S-EPMC5797297 | BioStudies | 2018-01-01

REPOSITORIES: biostudies

Similar Datasets

2014-01-01 | S-EPMC4171004 | BioStudies
2015-01-01 | S-EPMC5512113 | BioStudies
2020-01-01 | S-EPMC7163367 | BioStudies
2015-02-19 | E-MTAB-3244 | BioStudies
2020-01-01 | S-EPMC6989134 | BioStudies
2014-01-01 | S-EPMC4381956 | BioStudies
2008-01-01 | S-EPMC2760931 | BioStudies
2000-01-01 | S-EPMC16575 | BioStudies
2011-01-01 | S-EPMC3826122 | BioStudies
2015-02-19 | E-MTAB-3244 | ArrayExpress